A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

Inclusion criteria: * In overall general good health. * Females can enter and participate in this study if they are of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or if of childbearing potential, has a negative pregnancy test (urine) at screening and agrees to use GSK stipulated contraceptive methods. * Must be newly diagnosed with a first recognized episode of GH at the time of the Screening Visit or within 3 months prior to the Screening Visit. Exclusion criteria: * Known or suspected to be immunocompromised (e.g., subjects receiving immunosuppressive therapy or chemotherapy for malignancy, or are seropositive for HIV). * Received an investigational drug in the 30 days prior to the study. * Receiving systemic antiviral or immunomodulatory treatments. * Must not have received systemic antiviral treatments (e.g., valaciclovir, Famvir (famciclovir), acyclovir, lysine) within 3 days of starting study drug or immunomodulatory treatments in the 30 days before starting study drug. * Clinically significant impaired renal function as defined by a creatinine clearance \<30 ml/min, calculated using the Cockcroft-Gault formula. * Clinically significant impaired hepatic function defined as an ALT (alanine transaminase) level \> 5 times the normal upper limit. * Subjects with active liver disease. * Known to be hypersensitive to acyclovir, famciclovir, ganciclovir or any component of valaciclovir formulations. * Known resistance to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir or valganciclovir. * Subjects with malabsorption or vomiting syndrome or other gastrointestinal dysfunction that might impair drug pharmacokinetics. * Women contemplating pregnancy within the duration of the study drug dosing period. * Women who are pregnant and/or nursing mothers * Current history of alcohol or drug abuse. * Received suppressive (daily) therapy for genital herpes prior to enrollment.